Registry of patients with eosinophilia affecting the respiratory system
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
This study is gathering information from patients with eosinophilic lung diseases to better understand how their blood eosinophil levels relate to their breathing problems and overall health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Drugs / interventions | mepolizumab |
| Locations | 1 site (Innsbruck) |
| Trial ID | NCT04538937 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a registry of patients suffering from eosinophilic lung diseases, such as eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. It seeks to better understand the relationship between blood eosinophil counts and respiratory manifestations, as well as the potential for organ damage in conditions like hypereosinophilic syndrome. By characterizing different subtypes of eosinophils, the study hopes to clarify the clinical relevance of eosinophilia and improve therapeutic approaches. The study does not involve any interventions but focuses on collecting and analyzing patient data.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with documented blood eosinophilia and evidence of respiratory tract damage caused by eosinophils.
Not a fit: Patients under 18 years of age, pregnant individuals, or those with dementia or incapacitating conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of eosinophilic lung diseases, potentially enhancing patient outcomes.
How similar studies have performed: While the approach of characterizing eosinophils in respiratory diseases is not widely tested, there is ongoing interest in understanding eosinophilic conditions, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * documented blood eosinophilia ≥ 300 cells/µl * present tissue damage of the respiratory tract caused by eosinophils Exclusion Criteria: * age \< 18 years * pregnancy * dementia * incapacitated patients
Where this trial is running
Innsbruck
- University Clinic for Internal Medicine II — Innsbruck, Austria (Recruiting)
Study contacts
- Study coordinator: Ivan Tancevski, MD
- Email: ivan.tancevski@i-med.ac.at
- Phone: +43 50504 81602
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.